What's behind United Therapeutics's latest 3.6% stock surge?
United Therapeutics Corporation (UTHR) climbed 3.65% after the family trust of Chairperson & CEO Martine A. Rothblatt exercised stock options and sold shares in a scheduled Rule 10b5-1 plan, drawing increased investor attention. The advance is supported by the stock holding above all major moving averages, with momentum indicators backing the near-term uptrend, even as the longer-term trend alignment remains bearish and could restrain further gains.
Highlights
- A family trust linked to Martine A. Rothblatt exercised 9,500 United Therapeutics stock options at $117.76 per share and sold 9,500 shares at prices between $542.73 and $556.48 under a pre-arranged trading plan.
- The trust continues to hold 280,910 United Therapeutics stock options after the recent exercise and sale transactions.
- Shares of United Therapeutics trade above short-, medium-, and long-term moving averages, with technical indicators showing constructive momentum and resistance at $558.29; the five-day range is expected at $533.73 to $566.95.
Option exercise and stock sales by CEO trust influence market flows
On October 7, 2026, a family trust linked to Martine A. Rothblatt, Chairperson & CEO of United Therapeutics, exercised 9,500 stock options at $117.76 per share and sold 9,500 shares at weighted-average prices between $542.73 and $556.48. These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. The trust retained 280,910 stock options after these actions.
Short-term bullish signals tempered by longer-term bearish alignment
United Therapeutics is trading above the 20-day, 50-day, and 200-day moving averages ($509.82, $512.15, and $525.95), indicating bullish momentum on all timeframes. The price is approaching near-term resistance at $558.29, with immediate support at $550.01. Despite the short-term bullish setup, the longer-term trend alignment remains bearish, which could temper sustained upside momentum. Momentum indicators are mostly constructive: MACD and ADX show buy signals, RSI at 55.71 is neutral-to-bullish, and CCI favors buyers. Stochastic RSI is starting to flag overbought conditions. Bull/Bear Power at 20.44 indicates a buyer-dominated environment and signals overbought territory, while the Awesome Oscillator remains neutral. Intraday volatility stands at 3.99%, and the tone is strong, with some oscillators signaling near-term exhaustion.
Previously it was reported that United Therapeutics gained after a court ruled in its favor in a key patent dispute against Liquidia, impacting market dynamics in pulmonary hypertension treatments. The current technical environment adds a new dimension, as the stock's ability to consolidate or break above the $558.29 resistance level is now a critical factor for near-term trading direction.